Celgene (CELG) Receives Hold Rating from Piper Jaffray Companies
Celgene (NASDAQ:CELG)‘s stock had its “hold” rating reissued by stock analysts at Piper Jaffray Companies in a research report issued to clients and investors on Thursday. They currently have a $104.00 price target on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 2.24% from the stock’s current price.
A number of other equities analysts have also recently issued reports on the company. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 price objective for the company in a report on Wednesday. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the stock a “hold” rating in a report on Wednesday. Mizuho reiterated a “buy” rating and issued a $128.00 target price on shares of Celgene in a report on Wednesday. Guggenheim reiterated a “buy” rating and issued a $147.00 target price on shares of Celgene in a report on Wednesday, January 10th. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $129.98.
Celgene (NASDAQ CELG) traded down $0.30 on Thursday, reaching $101.72. The company had a trading volume of 9,270,570 shares, compared to its average volume of 6,480,000. Celgene has a one year low of $94.55 and a one year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The stock has a market cap of $80,090.00, a PE ratio of 23.99, a P/E/G ratio of 0.67 and a beta of 1.77.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. increased its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI increased its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares in the last quarter. Robecosam AG acquired a new position in Celgene during the 3rd quarter valued at about $114,000. Guidant Wealth Advisors acquired a new position in Celgene during the 3rd quarter valued at about $119,000. Finally, Capital Bank & Trust Co increased its position in Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares in the last quarter. 79.85% of the stock is owned by hedge funds and other institutional investors.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.